Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Male and females aged 18 to 75~* Recipients of cadaveric, living unrelated or living related kidney transplant, treated with CsA-ME, with or without corticosteroids, as primary immunosuppression~Exclusion criteria:~* Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ, other than kidney.~* Patients with any known hypersensitivity to MPA, EC-MPS or other components of the formulation (e.g. lactose).~* Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \< 1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline.~Other inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- EC MPS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).